γ-secretase inhibitor up-regulates vascular endothelial growth factor receptor-2 and endothelial nitric oxide synthase
- Authors:
- Yu-Hui Zou
- Yi-Qun Cao
- Lai-Xing Wang
- Yu-Hui Zhang
- Zhi-Jian Yue
- Jian-Min Liu
View Affiliations
Affiliations: Department of Neurosurgery, Changhai Hospital, Shanghai 200433, P.R. China
- Published online on: April 19, 2011 https://doi.org/10.3892/etm.2011.257
-
Pages:
725-729
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Although previous studies have shown that γ-secretase inhibitors significantly suppress tumor growth via anti-angiogenesis, the mechanism involved in the regulation of tumor angiogenesis by γ-secretase inhibitors has not been clearly understood. The objective of this study was to investigate the regulation of vascular endothelial growth factor receptor (VEGFR) and endothelial nitric oxide synthase (eNOS) by a γ-secretase inhibitor in the H5V mouse microvascular endothelial cell line. H5V cells were cultured with different concentrations of the γ-secretase inhibitor DAPT for 48 h and with 100 µmol/l DAPT at different incubation times. Protein and mRNA expression of VEGFR-1, VEGFR-2, VEGFR-3 and eNOS was measured by Western blotting and real-time PCR, respectively. The VEGFR-2 kinase inhibitor was used to assess the role of VEGFR-2 in eNOS regulation. We found that the γ-secretase inhibitor DAPT increased protein and mRNA expression of VEGFR-2 and eNOS, but decreased VEGFR-1 expression and had no significant effect on VEGFR-3. Up-regulation of eNOS was blocked by the VEGFR-2 kinase inhibitor. In conclusion, the γ-secretase inhibitor enhances VEGFR-2 and eNOS expression, and the up-regulation of eNOS is dependent on an increase in VEGFR-2. Thus, we suggest that administration of the γ-secretase inhibitor be combined with disruption of eNOS or interruption of VEGF signaling, which may improve the anti-angiogenic efficacy in tumor treatments.
View References
|
1.
|
Masuda S, Kumano K, Suzuki T, et al: Dual
antitumor mechanisms of Notch signaling inhibitor in a T-cell acute
lymphoblastic leukemia xenograft model. Cancer Sci. 100:2444–2450.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Caiado F, Real C, Carvalho T and Dias S:
Notch pathway modulation on bone marrow-derived vascular precursor
cells regulates their angiogenic and wound healing potential. PLoS
One. 3:e37522008. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Cook KM and Figg WD: Angiogenesis
inhibitors: current strategies and future prospects. CA Cancer J
Clin. 60:222–243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Michel T and Vanhoutte PM: Cellular
signaling and NO production. Pflugers Arch. 459:807–816. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Toda N, Ayajiki K and Okamura T:
Interaction of endothelial nitric oxide and angiotensin in the
circulation. Pharmacol Rev. 59:54–87. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Hirashima M: Regulation of endothelial
cell differentiation and arterial specification by VEGF and Notch
signaling. Anat Sci Int. 84:95–101. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Shawber CJ, Funahashi Y, Francisco E, et
al: Notch alters VEGF responsiveness in human and murine
endothelial cells by direct regulation of VEGFR-3 expression. J
Clin Invest. 117:3369–3382. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kroll J and Waltenberger J: VEGF-A induces
expression of eNOS and iNOS in endothelial cells via VEGF
receptor-2 (KDR). Biochem Biophys Res Commun. 252:743–746. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Wang Y, Nagase S and Koyama A: Stimulatory
effect of IGF-I and VEGF on eNOS message, protein expression, eNOS
phosphorylation and nitric oxide production in rat glomeruli, and
the involvement of PI3-K signaling pathway. Nitric Oxide. 10:25–35.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Facemire CS, Nixon AB, Griffiths R,
Hurwitz H and Coffman TM: Vascular endothelial growth factor
receptor 2 controls blood pressure by regulating nitric oxide
synthase expression. Hypertension. 54:652–658. 2009. View Article : Google Scholar : PubMed/NCBI
|
